Quick Answer
Xenon Pharmaceuticals Inc. reported Operating Income Loss of -$373.07 million for the year ending 2025.
- Xenon Pharmaceuticals Inc. showed a decrease of -33.6% in Operating Income Loss from 2024 to 2025.
- This data is from Xenon Pharmaceuticals Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2013: $1.94 million | Q2 2013: -$770.0 thousand | Q3 2013: $6.52 million | Q4 2013: $2.02 million | Q1 2014: $1.03 million | Q2 2014: $1.38 million | Q3 2014: $8.66 million | Q4 2014: $35.0 thousand | Q1 2015: -$6.14 million | Q2 2015: $199.0 thousand | Q3 2015: -$820.0 thousand | Q4 2015: -$2.60 million | Q1 2016: -$5.66 million | Q2 2016: -$6.37 million | Q3 2016: -$7.33 million | Q4 2016: -$5.46 million | Q1 2017: -$7.99 million | Q2 2017: -$7.89 million | Q3 2017: -$8.64 million | Q4 2017: -$8.05 million | Q1 2018: -$7.81 million | Q2 2018: -$7.59 million | Q3 2018: -$14.19 million | Q1 2019: -$11.76 million | Q2 2019: -$10.51 million | Q3 2019: -$8.95 million | Q1 2020: -$8.03 million | Q2 2020: -$646.0 thousand | Q3 2020: -$9.70 million | Q1 2021: -$16.06 million | Q2 2021: -$22.50 million | Q3 2021: -$15.60 million | Q1 2022: -$17.37 million | Q2 2022: -$30.32 million | Q3 2022: -$38.13 million | Q1 2023: -$49.05 million | Q2 2023: -$55.62 million | Q3 2023: -$55.68 million | Q1 2024: -$59.04 million | Q2 2024: -$69.10 million | Q3 2024: -$73.68 million | Q1 2025: -$72.74 million | Q2 2025: -$94.23 million | Q3 2025: -$96.34 million.
- Over the full 14 years of available data (2012 to 2025), Xenon Pharmaceuticals Inc.'s Operating Income Loss has declined by 11,732.2%.
- Historical annual values: Fiscal year 2025: -$373.07 million | Fiscal year 2024: -$279.30 million | Fiscal year 2023: -$214.05 million | Fiscal year 2022: -$129.14 million | Fiscal year 2021: -$78.99 million | Fiscal year 2020: -$31.30 million | Fiscal year 2019: -$42.82 million | Fiscal year 2018: -$38.04 million | Fiscal year 2017: -$32.58 million | Fiscal year 2016: -$24.82 million | Fiscal year 2015: -$9.36 million | Fiscal year 2014: $11.11 million | Fiscal year 2013: $9.71 million | Fiscal year 2012: -$3.15 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: